Genetics of Sjogren-Larsson Syndrome Medication

1. Sjogren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders. Acta Psychiatr Neurol Scand. 1957. 32:1-113.

2. Theile U. Sjogren-Larsson syndrome. Oligophrenia-ichthyosis-di-tetraplegia. Humangenetik. 1974. 22:91-118.

3. Rizzo WB, Dammann AL, Craft DA. Sjögren-Larsson syndrome. Impaired fatty alcohol oxidation in cultured fibroblasts due to deficient fatty alcohol:nicotinamide adenine dinucleotide oxidoreductase activity. J Clin Invest. 1988 Mar. 81(3):738-44. [QxMD MEDLINE Link]. [Full Text].

4. Rizzo WB, Craft DA. Sjogren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts. J Clin Invest. 1991 Nov. 88(5):1643-8. [QxMD MEDLINE Link].

5. De Laurenzi V, Rogers GR, Hamrock DJ, et al. Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet. 1996 Jan. 12(1):52-7. [QxMD MEDLINE Link].

6. Rizzo WB, Carney G. Sjogren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum Mutat. 2005 Jul. 26(1):1-10. [QxMD MEDLINE Link].

7. Rizzo WB. Sjogren-Larsson syndrome: fatty aldehyde dehydrogenase deficiency. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw Hill; 2001. Vol 2: 2239-58.

8. Jagell S, Liden S. Ichthyosis in the Sjogren-Larsson syndrome. Clin Genet. 1982 Apr. 21(4):243-52. [QxMD MEDLINE Link].

9. Jagell S, Gustavson KH, Holmgren G. Sjogren-Larsson syndrome in Sweden. A clinical, genetic and epidemiological study. Clin Genet. 1981 Apr. 19(4):233-56. [QxMD MEDLINE Link].

10. Jagell S, Heijbel J. Sjogren-Larsson syndrome: physical and neurological features. A survey of 35 patients. Helv Paediatr Acta. 1982. 37:519-530.

11. Willemsen MA, Cruysberg JR, Rotteveel JJ, et al. Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjogren-Larsson syndrome. Am J Ophthalmol. 2000 Dec. 130(6):782-9. [QxMD MEDLINE Link].

12. Willemsen MA, Van Der Graaf M, Van Der Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol. 2004 Apr. 25(4):649-57. [QxMD MEDLINE Link].

13. Willemsen MA, Lutt MA, Steijlen PM, et al. Clinical and biochemical effects of zileuton in patients with the Sjogren-Larsson syndrome. Eur J Pediatr. 2001 Dec. 160(12):711-7. [QxMD MEDLINE Link].

14. Haddad FS, Lacour M, Harper JI, Fixsen JA. The orthopaedic presentation and management of Sjogren-Larsson syndrome. J Pediatr Orthop. 1999 Sep-Oct. 19(5):617-9. [QxMD MEDLINE Link].

15. Cho KH, Shim SH, Kim M. Clinical, biochemical, and genetic aspects of Sjögren-Larsson syndrome. Clin Genet. 2018 Apr. 93 (4):721-730. [QxMD MEDLINE Link].

16. Rizzo WB. Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007 Jan. 90(1):1-9. [QxMD MEDLINE Link].

17. Verhoeven NM, Jakobs C, Carney G, Somers MP, Wanders RJ, Rizzo WB. Involvement of microsomal fatty aldehyde dehydrogenase in the alpha-oxidation of phytanic acid. FEBS Lett. 1998 Jun 16. 429(3):225-8. [QxMD MEDLINE Link].

18. van den Brink DM, van Miert JN, Dacremont G, et al. Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic acid. Mol Genet Metab. 2004 May. 82(1):33-7. [QxMD MEDLINE Link].

19. Rizzo WB, Heinz E, Simon M, Craft DA. Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjogren-Larsson syndrome. Biochim Biophys Acta. 2000 Dec 15. 1535(1):1-9. [QxMD MEDLINE Link].

20. Willemsen MA, Rotteveel JJ, de Jong JG, et al. Defective metabolism of leukotriene B4 in the Sjogren-Larsson syndrome. J Neurol Sci. 2001 Jan 15. 183(1):61-7. [QxMD MEDLINE Link].

21. Rizzo WB, Craft DA. Sjogren-Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J Lipid Res. 2000 Jul. 41(7):1077-81. [QxMD MEDLINE Link].

22. Rizzo WB, Craft DA, Somer T, et al. Abnormal fatty alcohol metabolism in cultured keratinocytes from patients with Sjogren-Larsson syndrome. J Lipid Res. 2008 Feb. 49(2):410-9. [QxMD MEDLINE Link].

23. Rizzo WB, S'aulis D, Jennings MA, Crumrine DA, Williams ML, Elias PM. Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion. Arch Dermatol Res. 2010 Jan 5. [QxMD MEDLINE Link].

24. Arai A, Takeichi T, Wakamoto H, et al. Ceramide profiling of stratum corneum in Sjögren-Larsson syndrome. J Dermatol Sci. 2022 Sep. 107 (3):114-22. [QxMD MEDLINE Link].

25. James PF, Zoeller RA. Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff's base modification of phospholipids: implications for Sj-ogren-Larsson syndrome. J Biol Chem. 1997 Sep 19. 272(38):23532-9. [QxMD MEDLINE Link].

26. van der Veen RL, Fuijkschot J, Willemsen MA, Cruysberg JR, Berendschot TT, Theelen T. Patients with Sjögren-Larsson syndrome lack macular pigment. Ophthalmology. 2010 May. 117(5):966-71. [QxMD MEDLINE Link].

27. Willemsen MA, Rotteveel JJ, van Domburg PH, et al. Preterm birth in Sjogren-Larsson syndrome. Neuropediatrics. 1999 Dec. 30(6):325-7. [QxMD MEDLINE Link].

28. Roy U, Das U, Pandit A, Debnath A. Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system. BMJ Case Rep. 2016 Apr 19. 2016:10.1136/bcr-2016-215110. [QxMD MEDLINE Link].

29. Lossos A, Khoury M, Rizzo WB, et al. Phenotypic variability among adult siblings with Sjogren-Larsson syndrome. Arch Neurol. 2006 Feb. 63(2):278-80. [QxMD MEDLINE Link].

30. Fuijkschot J, Maassen B, Gorter JW, Gerven M, Willemsen M. Speech-language performance in Sjogren-Larsson syndrome. Dev Neurorehabil. 2009 Apr. 12(2):106-12. [QxMD MEDLINE Link].

31. Kariminejad A, Barzgar M, Bozorgmehr B, et al. Novel mutations and a severe neurological phenotype in Sjögren-Larsson syndrome patients from Iran. Eur J Med Genet. 2018 Mar. 61 (3):139-44. [QxMD MEDLINE Link].

32. Willemsen MA, IjLst L, Steijlen PM, et al. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome. Brain. 2001. 124:1426-1437.

33. Fuijkschot J, Cruysberg JR, Willemsen MA, Keunen JE, Theelen T. Subclinical changes in the juvenile crystalline macular dystrophy in Sjögren-Larsson syndrome detected by optical coherence tomography. Ophthalmology. 2008 May. 115(5):870-5. [QxMD MEDLINE Link].

34. Sakai K, Akiyama M, Watanabe T, et al. Novel ALDH3A2 heterozygous mutations in a Japanese family with Sjogren-Larsson syndrome. J Invest Dermatol. 2006 Nov. 126(11):2545-7. [QxMD MEDLINE Link].

35. Ganemo A, Jagell S, Vahlquist A. Sjogren-larsson syndrome: a study of clinical symptoms and dermatological treatment in 34 Swedish patients. Acta Derm Venereol. 2009. 89(1):68-73. [QxMD MEDLINE Link].

36. Lacour M, Mehta-Nikhar B, Atherton DJ, Harper JI. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol. 1996 Jun. 134(6):1023-9. [QxMD MEDLINE Link].

37. Theile U. Sjogren-Larsson syndrome. Oligophrenia--ichthyosis--di-tetraplegia. Humangenetik. 1974 May 17. 22(2):91-118. [QxMD MEDLINE Link].

William B Rizzo, MD Professor, Department of Pediatrics, University of Nebraska Medical Center

William B Rizzo, MD is a member of the following medical societies: American Society of Human Genetics, Society for Inherited Metabolic Disorders

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Aldeyra Therapeutics (consultant)<br/>Received research grant from: Aldeyra Therapeutics.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lois J Starr, MD, FAAP Assistant Professor of Pediatrics, Clinical Geneticist, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center

Lois J Starr, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics

Disclosure: Nothing to disclose.

Luis O Rohena, MD, PhD, FAAP, FACMG Deputy Chief, Department of Pediatrics, Chief, Medical Genetics, San Antonio Military Medical Center; Associate Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD, PhD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Erawati V Bawle, MD, FAAP, FACMG Retired Professor, Department of Pediatrics, Wayne State University School of Medicine

Erawati V Bawle, MD, FAAP, FACMG is a member of the following medical societies: American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article